Papillary Adenocarcinoma — Trials

Papillary Adenocarcinoma — Trials · CancerIndex

Clinical trials

Registered studies

200 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 48
Recruiting: 19
Ph III recruiting: 3
Growth YoY: —
Industry share: 10%
Top sponsor: National Cancer Institute (NCI)
Termination share: 26.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (15)

clinicaltrialsPublishedShowing 51–77 of 77 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04624477	Active Surveillance and Surgery Outcomes in Low Risk Papillary Thyroid Cancer	active not recruiting	—	450	University Health Network, TorontoOTHER	1	Nov 28, 2025	clinicaltrials
NCT05768178	DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE)	recruiting	Phase 2 / Phase 3	30	Cancer Research UKOTHER	1	Nov 24, 2025